A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Glycomimetics Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 248,958 shares of GLYC stock, worth $57,260. This represents 0.0% of its overall portfolio holdings.

Number of Shares
248,958
Previous 108,800 128.82%
Holding current value
$57,260
Previous $30,000 40.0%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.16 - $0.32 $22,425 - $44,850
140,158 Added 128.82%
248,958 $42,000
Q2 2024

Aug 14, 2024

BUY
$0.24 - $3.04 $19,080 - $241,680
79,500 Added 271.33%
108,800 $30,000
Q1 2024

May 15, 2024

SELL
$2.55 - $3.49 $347,055 - $474,989
-136,100 Reduced 82.29%
29,300 $87,000
Q4 2023

Feb 14, 2024

SELL
$1.13 - $2.54 $60,567 - $136,144
-53,600 Reduced 24.47%
165,400 $390,000
Q3 2023

Nov 14, 2023

SELL
$1.29 - $1.73 $299,411 - $401,536
-232,102 Reduced 51.45%
219,000 $328,000
Q2 2023

Aug 14, 2023

SELL
$1.21 - $2.08 $173,511 - $298,267
-143,398 Reduced 24.12%
451,102 $784,000
Q1 2023

May 15, 2023

BUY
$1.25 - $4.05 $503,375 - $1.63 Million
402,700 Added 209.96%
594,500 $749,000
Q4 2022

Feb 14, 2023

SELL
$0.57 - $3.03 $8,607 - $45,753
-15,100 Reduced 7.3%
191,800 $581,000
Q3 2022

Nov 14, 2022

SELL
$0.55 - $0.9 $60,775 - $99,450
-110,500 Reduced 34.81%
206,900 $114,000
Q2 2022

Aug 15, 2022

SELL
$0.54 - $1.15 $38,556 - $82,110
-71,400 Reduced 18.36%
317,400 $190,000
Q1 2022

May 16, 2022

SELL
$1.0 - $1.58 $266,000 - $420,280
-266,000 Reduced 40.62%
388,800 $443,000
Q4 2021

Feb 14, 2022

BUY
$1.44 - $2.14 $48,672 - $72,332
33,800 Added 5.44%
654,800 $943,000
Q3 2021

Nov 15, 2021

SELL
$1.8 - $2.39 $158,400 - $210,320
-88,000 Reduced 12.41%
621,000 $1.36 Million
Q2 2021

Aug 16, 2021

SELL
$2.16 - $3.18 $376,488 - $554,274
-174,300 Reduced 19.73%
709,000 $1.65 Million
Q1 2021

May 17, 2021

BUY
$2.89 - $4.22 $276,573 - $403,854
95,700 Added 12.15%
883,300 $2.66 Million
Q4 2020

Feb 16, 2021

BUY
$2.69 - $4.24 $1.24 Million - $1.96 Million
462,300 Added 142.11%
787,600 $2.96 Million
Q3 2020

Nov 16, 2020

BUY
$3.07 - $5.0 $18,420 - $30,000
6,000 Added 1.88%
325,300 $999,000
Q2 2020

Aug 14, 2020

BUY
$2.06 - $3.76 $238,960 - $436,160
116,000 Added 57.06%
319,300 $1.2 Million
Q1 2020

May 15, 2020

BUY
$1.83 - $5.41 $275,781 - $815,287
150,700 Added 286.5%
203,300 $464,000
Q4 2019

Feb 14, 2020

BUY
$4.03 - $6.5 $211,978 - $341,900
52,600 New
52,600 $278,000

Others Institutions Holding GLYC

About GLYCOMIMETICS INC


  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $12.1M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.